Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
Objectives:To evaluate the relationship between bone mineral density (BMD) and biomarkers of bone turnover and inflammation in patients with ankylosing spondylitis (AS) treated with infliximab.Methods:Patients (n = 279) were randomly assigned (3:8) to receive placebo or 5 mg/kg infliximab every 6 we...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2009-02, Vol.68 (2), p.175-182 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 182 |
|---|---|
| container_issue | 2 |
| container_start_page | 175 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 68 |
| creator | Visvanathan, S van der Heijde, D Deodhar, A Wagner, C Baker, D G Han, J Braun, J |
| description | Objectives:To evaluate the relationship between bone mineral density (BMD) and biomarkers of bone turnover and inflammation in patients with ankylosing spondylitis (AS) treated with infliximab.Methods:Patients (n = 279) were randomly assigned (3:8) to receive placebo or 5 mg/kg infliximab every 6 weeks through week 96. At week 24, placebo-treated patients crossed over to infliximab 5 mg/kg. Starting at week 36, patients treated with infliximab received dose escalations to 7.5 mg/kg. Hip and spine BMD were measured (baseline, week 24, week 102) using dual-energy x-ray absorptiometry. Sera were analysed (baseline, week 24, week 102) for levels of bone alkaline phosphatase (BAP), osteocalcin, C-terminal cross-linking telopeptide of type I collagen (CTX), interleukin-6 (IL-6), vascular endothelial growth factor (VEGF) and transforming growth factor-β.Results:Patients treated with infliximab showed significantly greater median increases in BMD of the spine (2.5%, p |
| doi_str_mv | 10.1136/ard.2007.084426 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2605572</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21430496</sourcerecordid><originalsourceid>FETCH-LOGICAL-b553t-1aa11e92f3b68e334e410366b45c4e57f79e9e207432370a118eefa98f5038b63</originalsourceid><addsrcrecordid>eNqF0k1v1DAQBuAIgei2cOaGIiF6QMrW33YuldBSWqRSQAKulpMdt94m9mJnS_eH8H9xm2j5uPQUxfNkNJ68RfECoznGVByZuJwThOQcKcaIeFTMMBOqIkigx8UMIUQrVgu5V-yntMqvSGH1tNjDitVcUj4rfp1YC-2QymBL523nbl1vmjL4sjfxGuKuYPreDC6fG78sm-ChHDbRhxuI9ycmpdC6e5HKn264Gk3vPETTlUvwyQ3b3KlcZwR-mJTx19suJOcvy7QOfrnt3ODSs-KJNV2C59PzoPj2_uTr4qw6_3T6YfH2vGo4p0OFjcEYamJpIxRQyoBhRIVoGG8ZcGllDTUQJBklVKKMFYA1tbIcUdUIelAcj33Xm6aHZZvnytPqdcxLiFsdjNP_Vry70pfhRhOBOJckNzicGsTwYwNp0L1LLXSd8RA2SQuhMCOcPQgJZhTlX5Xhq__gKuRF5y1oLKVUXApZZ3U0qjaGlCLY3cwY6btk6JwMfZcMPSYjf_Hy76v-8VMUMng9AZNa09lofOvSzhFU10Rgml01OpcGuN3Vc1q0kFRyffF9oT9eiHeniy-f9Vn2b0bf9KsHp_wNCxXhAQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777857679</pqid></control><display><type>article</type><title>Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><creator>Visvanathan, S ; van der Heijde, D ; Deodhar, A ; Wagner, C ; Baker, D G ; Han, J ; Braun, J</creator><creatorcontrib>Visvanathan, S ; van der Heijde, D ; Deodhar, A ; Wagner, C ; Baker, D G ; Han, J ; Braun, J</creatorcontrib><description>Objectives:To evaluate the relationship between bone mineral density (BMD) and biomarkers of bone turnover and inflammation in patients with ankylosing spondylitis (AS) treated with infliximab.Methods:Patients (n = 279) were randomly assigned (3:8) to receive placebo or 5 mg/kg infliximab every 6 weeks through week 96. At week 24, placebo-treated patients crossed over to infliximab 5 mg/kg. Starting at week 36, patients treated with infliximab received dose escalations to 7.5 mg/kg. Hip and spine BMD were measured (baseline, week 24, week 102) using dual-energy x-ray absorptiometry. Sera were analysed (baseline, week 24, week 102) for levels of bone alkaline phosphatase (BAP), osteocalcin, C-terminal cross-linking telopeptide of type I collagen (CTX), interleukin-6 (IL-6), vascular endothelial growth factor (VEGF) and transforming growth factor-β.Results:Patients treated with infliximab showed significantly greater median increases in BMD of the spine (2.5%, p<0.001) and hip (0.5%, p = 0.033) at week 24 than those who received placebo (0.5% and 0.2% respectively). Baseline levels of IL-6, VEGF, osteocalcin, BAP and CTX were significantly correlated with increases in spinal BMD at weeks 24 and 102 in the infliximab group. In a multiple regression analysis, high baseline osteocalcin levels and early increases in BAP at week 2 were significantly associated with increases in BMD scores of the spine (week 102) and hip (weeks 24 and 102) in the infliximab group.Conclusions:Patients with AS who received infliximab showed significant increases in BMD scores over 2 years. While many significant correlations were observed between BMD scores of the hip and spine and biomarker levels, high baseline osteocalcin levels and early increases in BAP were consistently associated with increases in BMD scores.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.2007.084426</identifier><identifier>PMID: 18495735</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>Absorptiometry, Photon ; Adult ; Aged ; Aged, 80 and over ; Alkaline Phosphatase - blood ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal - therapeutic use ; Antirheumatic Agents - pharmacology ; Antirheumatic Agents - therapeutic use ; Biological and medical sciences ; Biomarkers ; Biomarkers - blood ; Bone density ; Bone Density - drug effects ; Bone Remodeling - drug effects ; Cervical Vertebrae - physiopathology ; Clinical and Epidemiological Research ; Diseases of the osteoarticular system ; Female ; Fundamental and applied biological sciences. Psychology ; Humans ; Inflammation ; Inflammation Mediators - blood ; Inflammatory joint diseases ; Infliximab ; Investigative techniques, diagnostic techniques (general aspects) ; Lumbar Vertebrae - physiopathology ; Male ; Medical sciences ; Middle Aged ; Osteoarticular system. Muscles ; Osteocalcin - blood ; Osteoporosis ; Patients ; Radiodiagnosis. Nmr imagery. Nmr spectrometry ; Skeleton and joints ; Spondylitis, Ankylosing - blood ; Spondylitis, Ankylosing - drug therapy ; Spondylitis, Ankylosing - physiopathology ; Studies ; Vascular endothelial growth factor ; Vertebrates: osteoarticular system, musculoskeletal system ; Young Adult</subject><ispartof>Annals of the rheumatic diseases, 2009-02, Vol.68 (2), p.175-182</ispartof><rights>Visvanathan et al 2009</rights><rights>2009 INIST-CNRS</rights><rights>Copyright: 2009 (c) Visvanathan et al 2009</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b553t-1aa11e92f3b68e334e410366b45c4e57f79e9e207432370a118eefa98f5038b63</citedby><cites>FETCH-LOGICAL-b553t-1aa11e92f3b68e334e410366b45c4e57f79e9e207432370a118eefa98f5038b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/68/2/175.full.pdf$$EPDF$$P50$$Gbmj$$Hfree_for_read</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/68/2/175.full$$EHTML$$P50$$Gbmj$$Hfree_for_read</linktohtml><link.rule.ids>114,115,230,314,776,780,881,3183,23550,27901,27902,77343,77374</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20992613$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18495735$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Visvanathan, S</creatorcontrib><creatorcontrib>van der Heijde, D</creatorcontrib><creatorcontrib>Deodhar, A</creatorcontrib><creatorcontrib>Wagner, C</creatorcontrib><creatorcontrib>Baker, D G</creatorcontrib><creatorcontrib>Han, J</creatorcontrib><creatorcontrib>Braun, J</creatorcontrib><title>Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Objectives:To evaluate the relationship between bone mineral density (BMD) and biomarkers of bone turnover and inflammation in patients with ankylosing spondylitis (AS) treated with infliximab.Methods:Patients (n = 279) were randomly assigned (3:8) to receive placebo or 5 mg/kg infliximab every 6 weeks through week 96. At week 24, placebo-treated patients crossed over to infliximab 5 mg/kg. Starting at week 36, patients treated with infliximab received dose escalations to 7.5 mg/kg. Hip and spine BMD were measured (baseline, week 24, week 102) using dual-energy x-ray absorptiometry. Sera were analysed (baseline, week 24, week 102) for levels of bone alkaline phosphatase (BAP), osteocalcin, C-terminal cross-linking telopeptide of type I collagen (CTX), interleukin-6 (IL-6), vascular endothelial growth factor (VEGF) and transforming growth factor-β.Results:Patients treated with infliximab showed significantly greater median increases in BMD of the spine (2.5%, p<0.001) and hip (0.5%, p = 0.033) at week 24 than those who received placebo (0.5% and 0.2% respectively). Baseline levels of IL-6, VEGF, osteocalcin, BAP and CTX were significantly correlated with increases in spinal BMD at weeks 24 and 102 in the infliximab group. In a multiple regression analysis, high baseline osteocalcin levels and early increases in BAP at week 2 were significantly associated with increases in BMD scores of the spine (week 102) and hip (weeks 24 and 102) in the infliximab group.Conclusions:Patients with AS who received infliximab showed significant increases in BMD scores over 2 years. While many significant correlations were observed between BMD scores of the hip and spine and biomarker levels, high baseline osteocalcin levels and early increases in BAP were consistently associated with increases in BMD scores.</description><subject>Absorptiometry, Photon</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alkaline Phosphatase - blood</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antirheumatic Agents - pharmacology</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Biomarkers - blood</subject><subject>Bone density</subject><subject>Bone Density - drug effects</subject><subject>Bone Remodeling - drug effects</subject><subject>Cervical Vertebrae - physiopathology</subject><subject>Clinical and Epidemiological Research</subject><subject>Diseases of the osteoarticular system</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammation Mediators - blood</subject><subject>Inflammatory joint diseases</subject><subject>Infliximab</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Lumbar Vertebrae - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Osteoarticular system. Muscles</subject><subject>Osteocalcin - blood</subject><subject>Osteoporosis</subject><subject>Patients</subject><subject>Radiodiagnosis. Nmr imagery. Nmr spectrometry</subject><subject>Skeleton and joints</subject><subject>Spondylitis, Ankylosing - blood</subject><subject>Spondylitis, Ankylosing - drug therapy</subject><subject>Spondylitis, Ankylosing - physiopathology</subject><subject>Studies</subject><subject>Vascular endothelial growth factor</subject><subject>Vertebrates: osteoarticular system, musculoskeletal system</subject><subject>Young Adult</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><sourceid>ACMMV</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0k1v1DAQBuAIgei2cOaGIiF6QMrW33YuldBSWqRSQAKulpMdt94m9mJnS_eH8H9xm2j5uPQUxfNkNJ68RfECoznGVByZuJwThOQcKcaIeFTMMBOqIkigx8UMIUQrVgu5V-yntMqvSGH1tNjDitVcUj4rfp1YC-2QymBL523nbl1vmjL4sjfxGuKuYPreDC6fG78sm-ChHDbRhxuI9ycmpdC6e5HKn264Gk3vPETTlUvwyQ3b3KlcZwR-mJTx19suJOcvy7QOfrnt3ODSs-KJNV2C59PzoPj2_uTr4qw6_3T6YfH2vGo4p0OFjcEYamJpIxRQyoBhRIVoGG8ZcGllDTUQJBklVKKMFYA1tbIcUdUIelAcj33Xm6aHZZvnytPqdcxLiFsdjNP_Vry70pfhRhOBOJckNzicGsTwYwNp0L1LLXSd8RA2SQuhMCOcPQgJZhTlX5Xhq__gKuRF5y1oLKVUXApZZ3U0qjaGlCLY3cwY6btk6JwMfZcMPSYjf_Hy76v-8VMUMng9AZNa09lofOvSzhFU10Rgml01OpcGuN3Vc1q0kFRyffF9oT9eiHeniy-f9Vn2b0bf9KsHp_wNCxXhAQ</recordid><startdate>20090201</startdate><enddate>20090201</enddate><creator>Visvanathan, S</creator><creator>van der Heijde, D</creator><creator>Deodhar, A</creator><creator>Wagner, C</creator><creator>Baker, D G</creator><creator>Han, J</creator><creator>Braun, J</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ Publishing Group</general><general>Elsevier Limited</general><scope>9YT</scope><scope>ACMMV</scope><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7QP</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20090201</creationdate><title>Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis</title><author>Visvanathan, S ; van der Heijde, D ; Deodhar, A ; Wagner, C ; Baker, D G ; Han, J ; Braun, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b553t-1aa11e92f3b68e334e410366b45c4e57f79e9e207432370a118eefa98f5038b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Absorptiometry, Photon</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alkaline Phosphatase - blood</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antirheumatic Agents - pharmacology</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Biomarkers - blood</topic><topic>Bone density</topic><topic>Bone Density - drug effects</topic><topic>Bone Remodeling - drug effects</topic><topic>Cervical Vertebrae - physiopathology</topic><topic>Clinical and Epidemiological Research</topic><topic>Diseases of the osteoarticular system</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammation Mediators - blood</topic><topic>Inflammatory joint diseases</topic><topic>Infliximab</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Lumbar Vertebrae - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Osteoarticular system. Muscles</topic><topic>Osteocalcin - blood</topic><topic>Osteoporosis</topic><topic>Patients</topic><topic>Radiodiagnosis. Nmr imagery. Nmr spectrometry</topic><topic>Skeleton and joints</topic><topic>Spondylitis, Ankylosing - blood</topic><topic>Spondylitis, Ankylosing - drug therapy</topic><topic>Spondylitis, Ankylosing - physiopathology</topic><topic>Studies</topic><topic>Vascular endothelial growth factor</topic><topic>Vertebrates: osteoarticular system, musculoskeletal system</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Visvanathan, S</creatorcontrib><creatorcontrib>van der Heijde, D</creatorcontrib><creatorcontrib>Deodhar, A</creatorcontrib><creatorcontrib>Wagner, C</creatorcontrib><creatorcontrib>Baker, D G</creatorcontrib><creatorcontrib>Han, J</creatorcontrib><creatorcontrib>Braun, J</creatorcontrib><collection>BMJ Open Access Journals</collection><collection>BMJ Journals:Open Access</collection><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Visvanathan, S</au><au>van der Heijde, D</au><au>Deodhar, A</au><au>Wagner, C</au><au>Baker, D G</au><au>Han, J</au><au>Braun, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2009-02-01</date><risdate>2009</risdate><volume>68</volume><issue>2</issue><spage>175</spage><epage>182</epage><pages>175-182</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Objectives:To evaluate the relationship between bone mineral density (BMD) and biomarkers of bone turnover and inflammation in patients with ankylosing spondylitis (AS) treated with infliximab.Methods:Patients (n = 279) were randomly assigned (3:8) to receive placebo or 5 mg/kg infliximab every 6 weeks through week 96. At week 24, placebo-treated patients crossed over to infliximab 5 mg/kg. Starting at week 36, patients treated with infliximab received dose escalations to 7.5 mg/kg. Hip and spine BMD were measured (baseline, week 24, week 102) using dual-energy x-ray absorptiometry. Sera were analysed (baseline, week 24, week 102) for levels of bone alkaline phosphatase (BAP), osteocalcin, C-terminal cross-linking telopeptide of type I collagen (CTX), interleukin-6 (IL-6), vascular endothelial growth factor (VEGF) and transforming growth factor-β.Results:Patients treated with infliximab showed significantly greater median increases in BMD of the spine (2.5%, p<0.001) and hip (0.5%, p = 0.033) at week 24 than those who received placebo (0.5% and 0.2% respectively). Baseline levels of IL-6, VEGF, osteocalcin, BAP and CTX were significantly correlated with increases in spinal BMD at weeks 24 and 102 in the infliximab group. In a multiple regression analysis, high baseline osteocalcin levels and early increases in BAP at week 2 were significantly associated with increases in BMD scores of the spine (week 102) and hip (weeks 24 and 102) in the infliximab group.Conclusions:Patients with AS who received infliximab showed significant increases in BMD scores over 2 years. While many significant correlations were observed between BMD scores of the hip and spine and biomarker levels, high baseline osteocalcin levels and early increases in BAP were consistently associated with increases in BMD scores.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>18495735</pmid><doi>10.1136/ard.2007.084426</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2009-02, Vol.68 (2), p.175-182 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2605572 |
| source | MEDLINE; BMJ Journals - NESLi2 |
| subjects | Absorptiometry, Photon Adult Aged Aged, 80 and over Alkaline Phosphatase - blood Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antirheumatic Agents - pharmacology Antirheumatic Agents - therapeutic use Biological and medical sciences Biomarkers Biomarkers - blood Bone density Bone Density - drug effects Bone Remodeling - drug effects Cervical Vertebrae - physiopathology Clinical and Epidemiological Research Diseases of the osteoarticular system Female Fundamental and applied biological sciences. Psychology Humans Inflammation Inflammation Mediators - blood Inflammatory joint diseases Infliximab Investigative techniques, diagnostic techniques (general aspects) Lumbar Vertebrae - physiopathology Male Medical sciences Middle Aged Osteoarticular system. Muscles Osteocalcin - blood Osteoporosis Patients Radiodiagnosis. Nmr imagery. Nmr spectrometry Skeleton and joints Spondylitis, Ankylosing - blood Spondylitis, Ankylosing - drug therapy Spondylitis, Ankylosing - physiopathology Studies Vascular endothelial growth factor Vertebrates: osteoarticular system, musculoskeletal system Young Adult |
| title | Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T00%3A25%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20infliximab%20on%20markers%20of%20inflammation%20and%20bone%20turnover%20and%20associations%20with%20bone%20mineral%20density%20in%20patients%20with%20ankylosing%20spondylitis&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Visvanathan,%20S&rft.date=2009-02-01&rft.volume=68&rft.issue=2&rft.spage=175&rft.epage=182&rft.pages=175-182&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.2007.084426&rft_dat=%3Cproquest_pubme%3E21430496%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777857679&rft_id=info:pmid/18495735&rfr_iscdi=true |